DK3433273T3 - Binding af molekyler til cd38 og pd-l1 - Google Patents
Binding af molekyler til cd38 og pd-l1 Download PDFInfo
- Publication number
- DK3433273T3 DK3433273T3 DK17713672.8T DK17713672T DK3433273T3 DK 3433273 T3 DK3433273 T3 DK 3433273T3 DK 17713672 T DK17713672 T DK 17713672T DK 3433273 T3 DK3433273 T3 DK 3433273T3
- Authority
- DK
- Denmark
- Prior art keywords
- molecules
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305350 | 2016-03-25 | ||
| PCT/EP2017/057220 WO2017162890A1 (en) | 2016-03-25 | 2017-03-27 | Binding molecules to cd38 and pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3433273T3 true DK3433273T3 (da) | 2022-02-14 |
Family
ID=55646510
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17713672.8T DK3433273T3 (da) | 2016-03-25 | 2017-03-27 | Binding af molekyler til cd38 og pd-l1 |
| DK21214273.1T DK3998285T3 (da) | 2016-03-25 | 2017-03-27 | Bindingsmolekyler til cd38 og pd-l1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21214273.1T DK3998285T3 (da) | 2016-03-25 | 2017-03-27 | Bindingsmolekyler til cd38 og pd-l1 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11505616B2 (da) |
| EP (2) | EP3998285B1 (da) |
| JP (2) | JP7529401B2 (da) |
| KR (1) | KR102361412B1 (da) |
| CN (2) | CN109476741B (da) |
| AU (1) | AU2017236183B2 (da) |
| CA (1) | CA3022143A1 (da) |
| DK (2) | DK3433273T3 (da) |
| ES (2) | ES3023551T3 (da) |
| FI (1) | FI3998285T3 (da) |
| HU (2) | HUE070697T2 (da) |
| PL (2) | PL3433273T3 (da) |
| PT (2) | PT3433273T (da) |
| RU (1) | RU2764201C2 (da) |
| SG (1) | SG11201808289SA (da) |
| WO (1) | WO2017162890A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3023551T3 (en) | 2016-03-25 | 2025-06-02 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| CN109563166B (zh) * | 2016-04-28 | 2022-12-20 | 拜奥穆尼克斯制药 | 靶向egfr和her2的双特异性抗体 |
| CA3052084A1 (en) * | 2017-01-09 | 2018-07-12 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| AU2018241881B2 (en) * | 2017-03-27 | 2024-10-10 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| JP2021508478A (ja) * | 2017-12-28 | 2021-03-11 | ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ | ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ） |
| CA3084398A1 (en) * | 2018-01-15 | 2019-07-18 | I-Mab Biopharma Us Limited | Modified c.kappa. and ch1 domains |
| CA3094318A1 (en) | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
| WO2020081786A1 (en) * | 2018-10-17 | 2020-04-23 | Immunome, Inc. | Exosome-targeting bispecific antibodies |
| CR20210326A (es) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
| WO2020136566A1 (en) | 2018-12-24 | 2020-07-02 | Sanofi | Multispecific binding proteins with mutant fab domains |
| WO2021207681A1 (en) * | 2020-04-10 | 2021-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted reduction of activated immune cells |
| JP2022045530A (ja) * | 2020-09-09 | 2022-03-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－１標的化ｉｌ－２変異体免疫サイトカインとヒトｐｄ－ｌ１に対する抗体との併用療法 |
| US20240228588A1 (en) * | 2021-01-11 | 2024-07-11 | Adimab, Llc | Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same |
| CN119654417A (zh) | 2022-06-10 | 2025-03-18 | 富士胶片戴奥辛思生物技术英国有限公司 | 细胞的制备方法、异源多聚体蛋白质的制造方法、双特异性抗体的制造方法、载体组、哺乳动物细胞、cho细胞和细胞池的制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| PT2857516T (pt) * | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW201120210A (en) * | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| JP2014511836A (ja) | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ， エセ．アー． | ヘテロ二量体免疫グロブリン |
| EP2543680A1 (en) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| HK1218930A1 (zh) | 2013-02-08 | 2017-03-17 | Abbvie Stemcentrx Llc | 新型多特异性结构 |
| AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| PL3122781T3 (pl) * | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| WO2015173756A2 (en) | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Bispecific antibodies |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CA2980189A1 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| ES3023551T3 (en) * | 2016-03-25 | 2025-06-02 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| CN109563166B (zh) | 2016-04-28 | 2022-12-20 | 拜奥穆尼克斯制药 | 靶向egfr和her2的双特异性抗体 |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| CA3052084A1 (en) | 2017-01-09 | 2018-07-12 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| AU2018241881B2 (en) * | 2017-03-27 | 2024-10-10 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| CN117843810A (zh) | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| GB201913079D0 (en) | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2017
- 2017-03-27 ES ES21214273T patent/ES3023551T3/es active Active
- 2017-03-27 AU AU2017236183A patent/AU2017236183B2/en active Active
- 2017-03-27 JP JP2019501761A patent/JP7529401B2/ja active Active
- 2017-03-27 EP EP21214273.1A patent/EP3998285B1/en active Active
- 2017-03-27 HU HUE21214273A patent/HUE070697T2/hu unknown
- 2017-03-27 PL PL17713672T patent/PL3433273T3/pl unknown
- 2017-03-27 PT PT177136728T patent/PT3433273T/pt unknown
- 2017-03-27 DK DK17713672.8T patent/DK3433273T3/da active
- 2017-03-27 SG SG11201808289SA patent/SG11201808289SA/en unknown
- 2017-03-27 EP EP17713672.8A patent/EP3433273B1/en active Active
- 2017-03-27 FI FIEP21214273.1T patent/FI3998285T3/fi active
- 2017-03-27 RU RU2018137419A patent/RU2764201C2/ru active
- 2017-03-27 DK DK21214273.1T patent/DK3998285T3/da active
- 2017-03-27 HU HUE17713672A patent/HUE057657T2/hu unknown
- 2017-03-27 WO PCT/EP2017/057220 patent/WO2017162890A1/en not_active Ceased
- 2017-03-27 KR KR1020187030790A patent/KR102361412B1/ko active Active
- 2017-03-27 CA CA3022143A patent/CA3022143A1/en active Pending
- 2017-03-27 US US16/088,181 patent/US11505616B2/en active Active
- 2017-03-27 CN CN201780028279.6A patent/CN109476741B/zh active Active
- 2017-03-27 PL PL21214273.1T patent/PL3998285T3/pl unknown
- 2017-03-27 PT PT212142731T patent/PT3998285T/pt unknown
- 2017-03-27 CN CN202310140318.9A patent/CN116284428A/zh active Pending
- 2017-03-27 ES ES17713672T patent/ES2906639T3/es active Active
-
2022
- 2022-05-25 JP JP2022085095A patent/JP2022116166A/ja active Pending
- 2022-11-17 US US18/056,279 patent/US12528877B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261942A (en) | Bcma binding molecules and methods of use thereof | |
| CY2024026I1 (el) | Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων | |
| DK3380522T5 (da) | Antistofmolekyler til april og anvendelser deraf | |
| DK3515478T3 (da) | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf | |
| DK3377612T3 (da) | Funktionel ekspression af monooxygenaser og fremgangsmåder til anvendelse | |
| DK3998285T3 (da) | Bindingsmolekyler til cd38 og pd-l1 | |
| PL3472207T3 (pl) | Wiążące cząsteczki wiążące się z PD-L1 i LAG-3 | |
| IL256416B (en) | Multispecific antigen-binding molecules and uses thereof | |
| IL261653A (en) | Ilt7 binding molecules and methods of using the same | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3116909T3 (da) | Antistofmolekyler til lag-3 og anvendelser deraf | |
| DK3265575T3 (da) | Cd20-bindende molekyler og anvendelser deraf | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3484469T3 (da) | Sammensætninger og fremgangsmåder til potentiering af antimikrober | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3364958T3 (da) | Modulatorer af sestrin-gator2-interaktion og anvendelser deraf | |
| DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3099800T3 (da) | Ekspression og oprensning af crm197 og beslægtede proteiner | |
| PL3374398T3 (pl) | Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie | |
| DK3128997T3 (da) | Bindingmolekyler specifikke for il-21 og anvendelser deraf | |
| DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf |